Progress on diagnostic and prognostic markers of pancreatic cancer
© 2023 YANG et al..
Pancreatic cancer is a malignant disease characterized by low survival and high recurrence rate, whose patients are mostly at the stage of locally advanced or metastatic disease when first diagnosed. Early diagnosis is particularly important because prognostic/predictive markers help guide optimal individualized treatment regimens. So far, CA19-9 is the only biomarker for pancreatic cancer approved by the FDA, but its effectiveness is limited by low sensitivity and specificity. With recent advances in genomics, proteomics, metabolomics, and other analytical and sequencing technologies, the rapid acquisition and screening of biomarkers is now possible. Liquid biopsy also occupies a significant place due to its unique advantages. In this review, we systematically describe and evaluate the available biomarkers that have the greatest potential as vital tools in diagnosing and treating pancreatic cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Oncology research - 31(2023), 2 vom: 12., Seite 83-99 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Hong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 13.06.2023 Date Revised 13.12.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.32604/or.2023.028905 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358059615 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358059615 | ||
| 003 | DE-627 | ||
| 005 | 20231227131320.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.32604/or.2023.028905 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM358059615 | ||
| 035 | |a (NLM)37304241 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Hong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Progress on diagnostic and prognostic markers of pancreatic cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.06.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 YANG et al. | ||
| 520 | |a Pancreatic cancer is a malignant disease characterized by low survival and high recurrence rate, whose patients are mostly at the stage of locally advanced or metastatic disease when first diagnosed. Early diagnosis is particularly important because prognostic/predictive markers help guide optimal individualized treatment regimens. So far, CA19-9 is the only biomarker for pancreatic cancer approved by the FDA, but its effectiveness is limited by low sensitivity and specificity. With recent advances in genomics, proteomics, metabolomics, and other analytical and sequencing technologies, the rapid acquisition and screening of biomarkers is now possible. Liquid biopsy also occupies a significant place due to its unique advantages. In this review, we systematically describe and evaluate the available biomarkers that have the greatest potential as vital tools in diagnosing and treating pancreatic cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Liquid biopsy | |
| 650 | 4 | |a Pancreatic cancer | |
| 650 | 4 | |a Systematic review | |
| 700 | 1 | |a Li, Wan |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Liwen |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yihui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yizhi |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Binbin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Sha |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Xiangjin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jinyi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Sen |e verfasserin |4 aut | |
| 700 | 1 | |a DU, Guanhua |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, B O |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hongquan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jinhua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology research |d 1996 |g 31(2023), 2 vom: 12., Seite 83-99 |w (DE-627)NLM012606715 |x 1555-3906 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g number:2 |g day:12 |g pages:83-99 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.32604/or.2023.028905 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |e 2 |b 12 |h 83-99 | ||